Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: a prospective study.
The incidence and consequences of HLA and non-HLA immunization were evaluated in 229 patients with aplastic thrombocytopenia. All patients were transfused with prestorage filtered red blood cells and platelets. On admission, 29 patients presented with HLA antibodies due to prior immunization by pregnancy and/or blood transfusions. Of the 200 patients showing no detectable HLA antibodies on admission, 164 could be evaluated. HLA antibodies developed in 2.7% (3 of 112) of the patients with a negative risk history of prior immunization. The occurrence of HLA antibodies in patients with a history of previous pregnancies or prior non-leukocyte-depleted blood transfusions (risk history positive) was 31% (16 of 52). Of the total of 48 patients who were or became alloimmunized, 92% (44 of 48) had a positive risk history. Ten patients with broad multispecific HLA antibodies with a panel reactivity (PRA) of greater than 70% required transfusions with HLA-matched platelets. Patients with HLA antibodies with lower PRA could be supported by random donor platelets. Two patients developed platelet-specific antibodies, causing transfusion refractoriness that necessitated selecting platelets by the absence of a platelet-specific antigen. Using prestorage leukocyte depletion of red cells and platelets with less than 5 x 10(6) residual leukocytes, 95% of the patients, including patients with a previous risk history or with HLA antibodies with low PRA, can be supported with random donor transfusions for the entire duration of their thrombocytopenic periods.
Novotny
V M
VM
Red Cross Blood Bank Leiden, The Netherlands.
van Doorn
R
R
Witvliet
M D
MD
Claas
F H
FH
Brand
A
A
D015746:Abdominal Pain / Q000209:etiology; D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000741:Anemia, Aplastic / Q000276:immunology / Q000628:therapy; D016824:Antigens, Human Platelet / Q000276:immunology*; D001793:Blood Preservation / Q000379:methods*; D001803:Blood Transfusion; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D017707:Erythrocyte Transfusion / Q000009:adverse effects; D005260:Female; D005334:Fever / Q000209:etiology; D005374:Filtration; D006680:HLA Antigens / Q000276:immunology*; D006402:Hematologic Diseases / Q000276:immunology / Q000628:therapy; D006801:Humans; D007114:Immunization; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007518:Isoantibodies / Q000096:biosynthesis*; D007938:Leukemia / Q000276:immunology / Q000628:therapy; D008223:Lymphoma / Q000276:immunology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010298:Parity; D017713:Platelet Transfusion / Q000009:adverse effects; D011446:Prospective Studies; D012307:Risk Factors; D013921:Thrombocytopenia / Q000276:immunology / Q000628:therapy
D016824:Antigens, Human Platelet; D006680:HLA Antigens; D007166:Immunosuppressive Agents; D007518:Isoantibodies